Sorrento Therapeutics, Inc. SRNE shares are trading higher on Monday after the company released results of its Phase 1B trial of resiniferatoxin in reduction of osteoarthritis knee pain.
Sorrento Therapeutics is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates.
Sorrento shares are trading up 4.58% at $10.08 during the time of publication on Monday. The stock has a 52-week high of $19.39 and a 52-week low of $1.39.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
